- Home
- AXTA vs LEGN Comparison
AXTA vs LEGN Comparison
Compare AXTA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXTA | LEGN |
|---|---|---|
| Founded | 1910 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AXTA | LEGN |
|---|---|---|
| Price | $29.61 | $19.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | $36.71 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 2.8M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $5,117,000,000.00 | N/A |
| Revenue This Year | $3.60 | $67.56 |
| Revenue Next Year | $2.94 | $43.20 |
| P/E Ratio | $17.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.28 | $16.24 |
| 52 Week High | $35.72 | $45.30 |
Technical Indicators
Market Signals| Indicator | AXTA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 25.02 | 50.28 |
| Support Level | $27.43 | $16.24 |
| Resistance Level | $31.01 | $23.68 |
| Average True Range (ATR) | 1.02 | 0.87 |
| MACD | -0.56 | 0.10 |
| Stochastic Oscillator | 10.22 | 33.74 |
Price Performance
Historical ComparisonAbout AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.